Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 36.96% | -98.81% | -136.82% | 152.45% | -326.55% |
| Total Depreciation and Amortization | 16.82% | -15.06% | 33.51% | -19.50% | -2.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.61% | 755.42% | 98.62% | -194.46% | 2,954.30% |
| Change in Net Operating Assets | -257.57% | 64.73% | 124.25% | -883.33% | 87.74% |
| Cash from Operations | 10.68% | -57.02% | 25.85% | -13.62% | 8.45% |
| Capital Expenditure | 52.33% | -77.06% | -153.49% | -53.57% | -7.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -104.03% | 221.78% | 10.70% | -320.12% | 91.86% |
| Cash from Investing | -104.24% | 220.96% | 10.54% | -320.64% | 92.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 70.00% | -900.00% | -- | -- | -760.00% |
| Issuance of Common Stock | -- | -- | -- | 72,572.86% | 13,900.00% |
| Repurchase of Common Stock | -- | 75.57% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 332.08% | 70.06% | -100.17% | 104,788.66% | 2,525.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -201.54% | 142.26% | -249.87% | 2,106.84% | 117.16% |